[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Patients were excluded if they had previous chemotherapy or radiotherapy treatment, presented early neoplasia, or died during the operations or for other reasons unrelated to cancer.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • For the survival analysis, cases with distant metastasis upon diagnosis were excluded.
  • There was predominance of the male gender (72.5%), diffuse histological type (55%) and infiltrative histological type (72.5%), and the more advanced stages (III and IV: 67.5%).
  • There was no association with intestinal metaplasia and/or H. pylori.
  • There was a positive correlation for intestinal histological type with PCNA and apoptotic indices, in 10 high power fields.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


2. Mizoshita T, Tsukamoto T, Toyoda T, Ban H, Nozaki K, Tatematsu M: Intestinal phenotypes of stomach cancers arising after Helicobacter pylori eradication in carcinogen-treated Mongolian gerbils. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):267-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal phenotypes of stomach cancers arising after Helicobacter pylori eradication in carcinogen-treated Mongolian gerbils.
  • AIMS: We have previously demonstrated the importance of gastric and intestinal phenotypic expression for the histogenesis of stomach cancer.
  • However, the phenotypes of stomach cancers arising after Helicobacter pylori (Hp) eradication have hitherto remained unclear.
  • METHODS: Totals of 6 and 20 advanced glandular stomach cancers were evaluated in Hp-eradicated and Hp-infected MGs treated with N-methyl-N-nitrosourea (MNU-MGs), using several gastrointestinal epithelial phenotypic markers.
  • The lesions were divided phenotypically into gastric (G type), gastric-and-intestinal mixed (GI type), intestinal (I type), and null (N type) phenotypes.
  • RESULTS: All 4 differentiated type lesions in Hp-eradicated MNU-MGs were classified as G type, while both of the undifferentiated lesions exhibit the GI type.
  • In Hp-infected MNU-MGs, the lesions were classified as 10 G, 8 GI, and 2 I types, with undifferentiated type lesions having more intestinal phenotypic expression than their differentiated counterparts (P< 0.01).
  • CONCLUSIONS: Our data suggest that the differentiated stomach cancers exhibit the G type in Hp-eradicated MNU-MGs, suggesting that a kind of non-neoplastic G type gland may be precancerous.
  • Intestinalization may still occur, especially in undifferentiated stomach cancers, even if Hp eradication is successful.
  • [MeSH-major] Adenocarcinoma / genetics. Helicobacter Infections / drug therapy. Helicobacter pylori / isolation & purification. Stomach Neoplasms / genetics. Stomach Neoplasms / microbiology
  • [MeSH-minor] Animals. Carcinogens. Disease Models, Animal. Gerbillinae. Methylnitrosourea / therapeutic use. Phenotype

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696744.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Carcinogens; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


3. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB: Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer; 2002 May 20;86(10):1578-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
  • Both 5-fluorouracil and doxorubicin are commonly used agents in chemotherapy of gastric cancer in adjuvant setting as well as metastatic disease.
  • We evaluated the expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase using immunohistochemistry in 103 locally advanced gastric cancer patients (stage IB-IV) who underwent 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection and investigated the association between their expression and clinicopathologic characteristics including prognosis of the patients.
  • High multidrug resistance-associated protein1 and P-glycoprotein expressions were associated with well and moderately differentiated histology (P<0.0001 and P=0.03, respectively) and intestinal type (P<0.0001 and P=0.009, respectively).
  • In conclusion, high expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase did not predict poor prognosis of gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Gastrectomy. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Thymidylate Synthase / analysis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunotherapy. Lentinan / administration & dosage. Life Tables. Male. Middle Aged. Mitomycin / administration & dosage. Picibanil / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] comCopyright 2002 Cancer Research UK
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):1903-6 [9677442.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1461(2):359-76 [10581367.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):171-7 [10638986.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4809-14 [11205224.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):186-92 [11161374.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):116-24 [2562856.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 7;82(21):1679-83 [1977924.001]
  • [Cites] Cancer. 1991 May 15;67(10):2454-8 [2015545.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4306-12 [1643628.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1650-4 [1360704.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] J Surg Oncol. 1995 Jan;58(1):63-9 [7823576.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):231-8 [8532000.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1681-7 [8608562.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):379-89 [8658222.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):372-7 [8903480.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1923-31 [9164203.001]
  • [Cites] Oncology. 1997 Sep-Oct;54(5):391-9 [9260601.001]
  • [Cites] Br J Cancer. 1997;76(4):486-93 [9275026.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1231-7 [9816292.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2054-9 [9827708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):673-80 [10100721.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):805-10 [10216496.001]
  • [Cites] Surg Today. 1999;29(5):401-6 [10333409.001]
  • [Cites] Br J Cancer. 1998;77(1):87-91 [9459150.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):661-6 [9477097.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1533-42 [9626474.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 12085207.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 37339-90-5 / Lentinan; 39325-01-4 / Picibanil; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2746581
  •  go-up   go-down


Advertisement
4. Gao SG, Wang LD, Fan ZM, Li JL, He X, Guo RF, Xie DL, He XW, Gao SS, Guo HQ, Wang JK, Feng XS, Ma BG: Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol; 2005 Aug 14;11(30):4634-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China.
  • AIM: To characterize the histochemical type and pattern of intestinal metaplasia (IM) adjacent to gastric cardia adenocarcinoma (GCA) and distal gastric cancer (GC) in Linzhou, Henan Province, China.
  • Radio- or chemotherapy was not applied to these patients before surgery.
  • RESULTS: The detection rate of IM in tissues adjacent to GCA tissues was 44.9%, which was significantly lower than that in GC tissues (80.64%, P<0.01).
  • The rates of both incomplete small intestinal and colonic IM types identified by histochemistry in GCA tissues (31.82% and 63.64%, respectively) were significantly higher than those in GC (5.33% and 21.33%, respectively, P<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094701.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065871; United States / NCI NIH HHS / CA / CA65871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4615402
  •  go-up   go-down


5. Peterson WL: Review article: Helicobacter pylori and gastric adenocarcinoma. Aliment Pharmacol Ther; 2002 Mar;16 Suppl 1:40-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: Helicobacter pylori and gastric adenocarcinoma.
  • Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries.
  • Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself.
  • Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma.
  • Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Stomach Neoplasms / etiology
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Therapy, Combination. Gerbillinae. Humans

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11849127.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


6. Hamilton K, Chiappori A, Olson S, Sawyers J, Johnson D, Washington K: Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma. Mod Pathol; 2000 May;13(5):475-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma.
  • Neuroendocrine differentiation is common in adenocarcinomas of the stomach and colon and may be associated with a slightly better prognosis in gastric adenocarcinoma.
  • Fifty-eight cases of esophageal adenocarcinoma (15 biopsies, 43 resections) from 52 patients were stained with a monoclonal antibody to chromogranin (CG).
  • Medical records were reviewed for tumor stage, response to therapy, and patient survival.
  • Thirty-two patients received radiation and chemotherapy, and four received radiation.
  • Tumors with CG-positive cells were moderately to poorly differentiated, and many consisted of large cribriform glands, similar to intestinal-type adenocarcinomas.
  • There was no difference in tumor stage at surgery or survival time between CG-positive and CG-negative tumors.
  • In summary, neuroendocrine differentiation is common in BE and is retained in low- and high-grade dysplasia but is usually lost in esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10824917.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68485
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Chromogranins
  •  go-up   go-down


7. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C: Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res; 2008 Jun;41(6):539-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the DNA methylation status of ANAPC1, CDKN2A and TP53 by methylation-specific PCR in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric mucosa in individuals from Northern Brazil.
  • Patients had never been submitted to chemotherapy or radiotherapy, nor did they have any other diagnosed cancer.
  • CDKN2A methylation was not detected in any normal gastric mucosa; however, the CDKN2A promoter was methylated in 30.4% of gastric cancer samples, with 35% methylation in diffuse-type and 26.9% in intestinal-type cancers.
  • CDKN2A methylation was associated with the carcinogenesis process for ~30% diffuse-type and intestinal-type compared to non-neoplastic samples.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622497.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ANAPC1 protein, human; 0 / Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


8. Stepanov EA, Razumovskiĭ AIu, Bataev S-, Alkhasov AB, Nurik VI, Mart'ianov AV, Bogaeva II: [Treatment policy for children with gastroesophageal reflux complicated by Barrett esophagus]. Khirurgiia (Mosk); 2002;(11):8-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment policy for children with gastroesophageal reflux complicated by Barrett esophagus].
  • Twenty-four-hour pH-metry and manometry of the esophagus, scintigraphy and contrast roentgenoscopy of the esophagus were used for diagnosis of GER.
  • All the children underwent biopsy of mucosa membrane of distal esophagus.
  • Metaplasia of esophageal epithelium by intestinal type (IT) in combination with one by gastric type (GT) were revealed in 8 children, metaplasia by gastric type alone (epithelium of gastric and fundal parts of the stomach)--in 8 children.
  • It esophageal stenosis is not long or is absent, fundoplication by Nissen (4 children) and drug therapy (6 children) are performed.
  • Other methods of treatment do not exclude probability of esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / etiology. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / therapy
  • [MeSH-minor] Adolescent. Biopsy. Child. Child, Preschool. Combined Modality Therapy / standards. Diet, Reducing. Drug Therapy, Combination. Esophagoplasty / methods. Esophagus / drug effects. Esophagus / pathology. Esophagus / physiopathology. Esophagus / surgery. Female. Humans. Infant. Male. Metaplasia. Supine Position / physiology


9. Uslu A, Karaca C, Nart A, Adagülü H, Aykas A, Gürkan A, Dogan M: Adjuvant chemotherapy in a unique population of patients with gastric cancer undergoing surgery. Hepatogastroenterology; 2004 Jul-Aug;51(58):1245-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in a unique population of patients with gastric cancer undergoing surgery.
  • Complementary therapy for the control of systemic microscopic disease should be taken into consideration in patients whom surgery with curative intent was performed.
  • RESULTS: The mean disease-free and overall survival rates were 41 and 48 months (p: 0.78) and 42 and 53 months (p: 0.43) in the control and chemotherapy groups, respectively.
  • CONCLUSIONS: Although statistical significance has not been achieved in this study, a trend toward adjuvant chemotherapy has emerged in that unique group of patients with moderately differentiated (intestinal type) adenocarcinoma of the stomach undergoing curative surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / surgery. Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Drug Therapy, Combination. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Lymph Node Excision. Male. Middle Aged. Odds Ratio

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239288.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, Park SR: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol; 2010 Dec;17(12):3163-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy.
  • BACKGROUND: We conducted the current study to investigate the clinical outcomes of metastatic gastric carcinoma (MGC) patients who experienced gastrointestinal (GI) perforation during palliative chemotherapy and to examine the prognostic factors associated with survival after perforation.
  • METHODS: We reviewed the medical records of patients at the Center for Gastric Cancer of the National Cancer Center, Korea who developed GI perforation during palliative chemotherapy between January 2001 and December 2008.
  • RESULTS: Of the 1,856 patients who received palliative chemotherapy for MGC, 32 patients (1.7%) developed GI perforation during chemotherapy.
  • Patients with perforation at the primary gastric site were more likely to have ulcerative gastric cancer lesion (90.5 vs. 40.0%, P = 0.034) or gastric tumor bleeding (28.6 vs. 0%, P = 0.298), and less likely to have Bormann type IV (14.3 vs. 60.0%, P = 0.062), than patients with perforation at nongastric sites.
  • In 14 patients (43.8%) who resumed chemotherapy after perforation, the disease control rate was 57.1%, and median overall survival (OS) after perforation was 7.5 months [95% confidence interval (CI), 6.0-9.0 months].
  • In all patients, median OS following perforation was 4.0 months (95% CI, 1.5-6.6 months), and multivariate analysis revealed that differentiated tumor histology, response to chemotherapy before perforation, and absence of septic shock at time of perforation were significantly associated with favorable OS after perforation.
  • CONCLUSIONS: As patients experiencing GI perforation during palliative chemotherapy have heterogeneous clinical presentation, we need to adopt different approaches in the management of the patients that are compatible with the favorable prognostic factors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Signet Ring Cell / drug therapy. Intestinal Perforation / chemically induced. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585878.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Mizoshita T, Kataoka H, Kubota E, Shimura T, Mori Y, Wada T, Ogasawara N, Sasaki M, Kamiya T, Sakamoto M, Akamo Y, Joh T: An endocrine cell carcinoma with gastric-and-intestinal mixed phenotype adenocarcinoma component in the stomach. Dig Endosc; 2009 Oct;21(4):258-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An endocrine cell carcinoma with gastric-and-intestinal mixed phenotype adenocarcinoma component in the stomach.
  • A 77-year-old man complained of bodyweight loss, and a Borrmann 3 type lesion was observed endoscopically in the anterior wall of angular region of the stomach.
  • The patient underwent distal gastrectomy plus systemic lymph node (LN) dissection (D2 LN dissection), and pathological examination revealed ECC invading the subserosa, and no LN metastasis (pT2N0M0).
  • None of the gastric and intestinal endocrine cell marker expression was apparent in the ECC cells.
  • The lesion also contained a moderately differentiated type tubular adenocarcinoma component, which was judged to be gastric-and-intestinal mixed (GI type) phenotype, using gastric and intestinal exocrine cell markers.
  • The patient now (March 2008, about 19 months since the surgery) continues this chemotherapy with no recurrence.
  • In conclusion, we experienced ECC with a GI type adenocarcinoma component.
  • The ECC cases with the GI type adenocarcinoma component may have a relatively good prognosis, being similar to the results of advanced gastric cancers from the viewpoint of gastric and intestinal phenotypic expression.
  • [MeSH-major] Carcinoma / pathology. Endoscopy. Enteroendocrine Cells / pathology. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961526.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


12. Ichimura T, Chin K, Kobayashi K, Osaka M, Kuboki Y, Ogura M, Shinozaki E, Suenaga M, Matsuzaka S, Mizunuma N, Hatake K: [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2131-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy].
  • The incidence of gastrointestinal bleeding, thromboembolic events and gastrointestinal perforation during chemotherapy with metastatic or unresectable gastric cancer has been unknown.
  • PATIENTS AND METHODS: We investigated metastatic or unresectable gastric cancer patients who received chemotherapy during January 2002 to December 2006.
  • Grade≥3 (CTCAE v3.0) adverse events from the first day of chemotherapy to 1 month after the last day of chemotherapy were investigated.
  • RESULTS: A total of 292 patients received chemotherapy.
  • Patient characteristics were as follows: median age 63.5 years (range, 28 to 87); performance status 0/1/2/3: 129/129/31/3; male: female, 206:86, histopathological type intestinal/diffuse/unclassified-adenocarcinoma/others: 91/139/58/4.
  • We should be aware of the frequency of these toxicities in the treatment of gastric cancer.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Intestinal Perforation / etiology. Stomach Neoplasms / drug therapy. Thromboembolism / etiology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084812.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Nagahori Y, Nagahori K, Hamaguchi Y, Fukushima T, Masui H, Mogaki M, Abe T: [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1555-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
  • Several chemotherapy regimens combining CPT-11 and CDDP for advanced gastric cancer have been reported to demonstrate high response rates and high incidence of severe toxicity.
  • PURPOSE: We conducted a combination chemotherapy regimen of low-dose CDDP and CPT-11 to prolong the time to progression with less toxicity.
  • PATIENTS AND METHODS: Seven patients with histologically-confirmed intestinal type of gastric adenocarcinoma were enrolled in this study.
  • All patients were male, and their age at diagnosis ranged from 52 to 76 with a mean age of 64.8.
  • Six patients received combination chemotherapy with CPT-11 and CDDP after the gastrectomy (stage I b: 1, II : 3, III b: 1, IV: 1).
  • Only chemotherapy was administered in one patient because of a far advanced primary lesion and metastatic tumors.
  • CONCLUSION: The combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may achieve a prolonged median survival time in patients with intestinal- type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Gastroscopy. Humans. Intestinal Neoplasms / classification. Intestinal Neoplasms / pathology. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799911.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S: Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer; 2001;4(3):144-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
  • METHODS: The subjects comprised 65 patients with advanced gastric cancer treated with CPT-11 (70mg/m2, day 1, day 15) and CDDP (80mg/m2, day 1) as first-line chemotherapy between April 1993 and March 1999.
  • Patient backgrounds, response rates, response durations, times to progression, and survival rates were investigated retrospectively.
  • There were no treatment-related or early deaths within 30 days from the last treatment day.
  • The median survival times of all patients, patients with an intestinal type of adenocarcinoma, and patients with a diffuse type were 365, 472, and 291 days, respectively.
  • Multivariate analysis showed that the histological type of cancer was a significant independent prognostic factor (P = 0.0169).
  • CONCLUSION: This retrospective study confirmed the efficacy and feasibility of this combination therapy in clinical practice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760080.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


15. Jalle T, Gérard C, Lada PE, Sagan C, Gournay J, Arnaud JP, Paineau J, Hamy A: [Hepatoid adenocarcinoma of the stomach. A case report]. Ann Chir; 2006 Mar;131(3):213-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatoid adenocarcinoma of the stomach. A case report].
  • Hepatoid adenocarcinoma of the stomach is a very rare tumor with a poor prognosis.
  • Diagnosis should be pointed out if elevated serum level of alpha-fetoprotein (AFP) is detected with gastric tumor.
  • Histologically, the tumor is an adenocarcinoma of intestinal type including foci of hepatoïd differenciation.
  • We report a case of a 66 year-old man presenting an advanced stage of hepatoid adenocarcinoma of the stomach, treated by gastrectomy followed by chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Liver Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293220.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Intestinal adenocarcinomas were analysed immunohistochemically for the presence of ER alpha, beta and beta cx.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


17. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K: Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep; 2000 Jul-Aug;7(4):841-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
  • Recent studies have indicated that vascular endothelial growth factor (VEGF) is related to drug delivery through angiogenesis and vascular permeability.
  • In this study, we evaluated the efficacy and toxicity of continuous infusion of 5-FU and low dose cisplatin infusion as first-line treatment in patients with unresectable gastric adenocarcinoma.
  • We also examined the relationship between chemotherapy response and immunohistochemical expression of VEGF in the biopsy samples of gastric primary.
  • This treatment was repeated weekly for 3 consecutive weeks.
  • Patients with intestinal histologic type (10/12) and good performance status ([PS], 13/18) showed good response rate (83.3%, and 72.2%, respectively) compared to patients with diffuse histologic type (4/18) and poor PS [(1/12) 22.2%, and 8.
  • Multivarite analysis revealed that VEGF-positive and good PS had a significant impact on chemotherapy response in this treatment.
  • Continuous infusion of 5-FU and low dose cisplatin infusion is an effective treatment for patients with unresectable gastric carcinoma, and VEGF expression may be a useful predictor of chemotherapy response in this regimen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endothelial Growth Factors / analysis. Lymphokines / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Infusions, Intravenous. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Survival Rate. Time Factors. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854555.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Cammarota G, Larocca LM, D'Ugo D, Persiani R, Cianci R, Nocente R, Picciocchi A, Gasbarrini G: Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis? Hepatogastroenterology; 2001 Jan-Feb;48(37):104-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis?
  • Low-grade primary MALT (mucosa-associated lymphoid tissue) lymphoma of the stomach is a neoplasm with an indolent course and a good prognosis.
  • Patients with this type of neoplasm seem to have a higher risk for other neoplasms.
  • Of interest is the association of gastric MALT lymphoma with gastric adenocarcinoma of intestinal type.
  • We report the case of a patient, with a history of H. pylori-related gastritis, in whom a diagnosis of synchronous gastric adenocarcinoma of intestinal type and low-grade MALT lymphoma, occurring as collision tumors, was made.
  • The patient underwent two cycles of neoadjuvant EEP (etoposide, epirubicin, cisplatin) chemotherapy.
  • [MeSH-major] Adenocarcinoma / microbiology. Gastritis / complications. Helicobacter Infections / complications. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / microbiology. Neoplasms, Multiple Primary. Stomach Neoplasms / microbiology
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268940.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Sasaki T, Koizumi W, Higuchi K, Ishido K, Ae T, Nakatani K, Katada C, Tanabe S, Saigenji K: [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint]. Gan To Kagaku Ryoho; 2007 Jul;34(7):988-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
  • Type 4 gastric cancer has a poor prognosis compared with other types of advanced gastric cancer because of the high incidence of peritoneal metastasis which causes intestinal obstruction, hydronephrosis, or obstructive jaundice.
  • Surgical treatment is often only palliative, and systematic chemotherapy is considered to be important for long survival.
  • S-1 showed a higher response rate for undifferentiated-type adenocarcinoma, and S-1 alone or its combination regimens demonstrated greater anti-tumor effects and longer survival time for gastric linitis plastica compared with conventional 5-FU regimens in our historical control study (response rate: S-1/non S-1 57.9%/27.9%, p<0.01; MST: S-1/non S-1 402 days/213 days, p<0.01).
  • S-1 regimens may also improve the survival in patients with type 4 gastric cancer in neoadjuvant or adjuvant settings, but further prospective studies are warranted to prove its significance.
  • Paclitaxel also has a high response rate for undifferentiated-type adenocarcinoma, and can be expected to show high efficacy for peritoneal dissemination.
  • Irinotecan should not be administered in case of intestinal obstruction because its toxicity may be increased.
  • However,survival of patients with type 4 gastric cancer may improve with the availability of active agents like S-1, taxanes, irinotecan as reported in colorectal cancer.
  • Therefore,irinotecan should be administered carefully before intestinal obstruction occurs.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Administration Schedule. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637532.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Raderer M, Püspök A, Stummvoll G, Längle F, Chott A: Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease. Scand J Gastroenterol; 2003 Mar;38(3):294-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.
  • BACKGROUND: Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) arises in lymphoid tissue acquired through chronic antigenic stimulation as exemplified by Helicobacter pylori.
  • The detection of a signet ring cell carcinoma during follow-up endoscopy after successful therapy of MALT lymphoma in a patient with Sjögren's syndrome prompted us to analyse the frequency of subsequent gastric cancer in patients with underlying autoimmune disease (AD).
  • Data analysed included the type of AD, stage of MALT lymphoma, H. pylori status, treatment for MALT lymphoma and response, follow-up, the presence of a secondary cancer, and time to development of cancer.
  • In all patients, histologic samples were reassessed for the extent of gastritis, presence of intestinal metaplasia or focal atrophy at the time of lymphoma diagnosis.
  • RESULTS: A total of eight patients with overt AD at the time of diagnosis of MALT lymphoma were identified.
  • All patients had early stage MALT lymphoma restricted to the mucosa and submucosa at the time of diagnosis, and the presence of H. pylori was found in all cases.
  • Two of these patients achieved complete remission (CR) of the lymphoma following H. pylori eradication, while six were judged unresponsive and underwent chemotherapy, resulting in CR in all cases.
  • One patient died from stroke while being in CR for 2 months following chemotherapy.
  • Two patients (25%) developed early cancer limited to the gastric mucosa while being in CR from lymphoma for 9 and 27 months, respectively, and underwent partial gastrectomy.
  • In the remaining 4 patients, no evidence of lymphoma recurrence or a second malignancy has been found so far by regular follow-up every 3 months for a time-span between 52 and 63 months after initial diagnosis.
  • [MeSH-major] Autoimmune Diseases / therapy. Gastric Mucosa / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Aged. Antineoplastic Combined Chemotherapy Protocols. Austria. Biopsy. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / therapy. Endosonography. Female. Follow-Up Studies. Humans. Metaplasia. Middle Aged. Neoplasm Staging. Polymyalgia Rheumatica / diagnosis. Polymyalgia Rheumatica / therapy. Pyloric Antrum / pathology. Remission Induction. Severity of Illness Index. Sjogren's Syndrome / diagnosis. Sjogren's Syndrome / therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737445.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


21. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The highest rates of HER-2 over-expression are observed in patients with OGJ rather than gastric tumours and intestinal-type rather than diffuse or mixed histology.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • Trastuzumab plus FP chemotherapy is now the standard of care for patients with advanced gastric and OGJ cancers which over-express HER-2.
  • Further research to evaluate trastuzumab delivered beyond progression, in combination with alternative first-line chemotherapy regimens, and in the perioperative and adjuvant setting is urgently needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Clinical Trials, Phase III as Topic. Forecasting. Genes, erbB-2. Humans. Multicenter Studies as Topic. Quinazolines / therapeutic use. Randomized Controlled Trials as Topic. Receptor, ErbB-2. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


22. Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric junction. Surg Oncol; 2000 Jul;9(1):35-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the Western world, there has been an alarming rise in the incidence and prevalence of adenocarcinoma arising at the esophagogastric junction during recent decades.
  • Epidemiological, clinical and pathological data support a sub-classification of adenocarcinomas arising in the vicinity of the esophagogastric junction (AEG) into adenocarcinoma of the distal esophagus (Type I), true carcinoma of the cardia (Type II) and subcardial carcinoma (Type III).
  • While most, if not all, adenocarcinomas of the distal esophagus arise from areas with specialized intestinal metaplasia, which develop as a consequence of chronic gastroesophageal reflux, the etiology and pathogenesis of true carcinoma of the gastric cardia and subcardial gastric cancer is not clear at present.
  • Although a subgroup of true carcinomas of the gastric cardia may also develop within short segments of intestinal metaplasia at the esophagogastric junction, a causal relation between these tumors and gastroesophageal reflux has been difficult to establish.
  • Irrespective of the etiology, a complete removal of the primary tumor and its lymphatic drainage has to be the primary goal of any surgical approach to adenocarcinoma of the esophagogastric junction.
  • Our experience in the management of more than 1000 such patients during the past 18 years suggests that an individualized therapeutic strategy oriented by tumor type and stage results in survival rates superior to those reported with a more indiscriminate approach.
  • This individualized strategy prescribes a transmediastinal esophagectomy with lymphadenectomy in the lower posterior mediastinum and along the celiac axis for Type I tumors, extended total gastrectomy with transhiatal resection of the distal esophagus and D2 lymphadenectomy for Type II and Type III tumors, a limited resection of the esophagogastric junction and distal esophagus with interposition of a pedicled jejunal segment for uT1N0 tumors, and neoadjuvant chemotherapy followed by resection for uT3/T4 tumors.
  • Extensive preoperative staging is essential to allow correct selection of the appropriate therapeutic strategy using this tailored approach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Algorithms. Combined Modality Therapy. Decision Trees. Esophagectomy. Gastrectomy. Gastroesophageal Reflux / complications. Humans. Incidence. Lymph Node Excision. Neoplasm Staging. Preoperative Care. Prevalence. Splenectomy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525305.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 36
  •  go-up   go-down


23. Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, Gastinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G: [Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir; 2009 Aug;134(4):362-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of and therapy for gastric cancer--work-flow].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms--Workflow.
  • AIM: This review comments on the diagnosis and treatment of gastric cancer in the classical meaning--excluding adenocarcinoma of the -oesophagogastric junction.
  • Algorithms of diagnosis and care with respect to tumour stage are presented.
  • PREOPERATIVE DIAGNOSIS: Besides oesophagogastroduodenoscopy, endoscopic ultrasonography is necessary for the accurate diagnosis of T categories and as a selection criterion for neoadjuvant chemotherapy.
  • Computed tomography is recommended for preoperative evaluation of tumours > T1, laparoscopy has become an effective stag-ing tool in T3 and T4 tumours avoiding unnecessary laparotomies and improving the detection of small -liver and peritoneal metastases.
  • TREATMENT: Endoscopic mucosal resection and submucosal dissection are indicated in superficial cancer confined to the mucosa with special characteristics (T1 a / no ulcer / G1, 2 / Laurén intestinal / L0 / V0 / tumour size < 2 cm).
  • In all other cases total gastrectomy or distal subtotal gastric resection are indicated, the latter in cases of tumours located in the distal two-thirds of the stomach.
  • Standard lymphadenectomy (LAD) is the D2 LAD without distal pancreatectomy and splenectomy.
  • The Roux-en-Y oesophagojejunostomy is still the preferred type of reconstruction.
  • Perioperative chemotherapy and postoperative chemoradiotherapy are based on the MAGIC and MacDonald trials.
  • Perioperative chemotherapy should be performed in patients with T3 and T4 tumours with the aim to increase the likelihood of curative R0-resection by downsizing the tumour.
  • Adjuvant postoperative chemotherapy cannot be recommended since its benefit has so far not been proven in randomised trials.
  • [MeSH-major] Gastrectomy. Lymph Node Excision. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Humans. Laparoscopy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Palliative Care. Perioperative Care. Peritoneal Lavage. Prognosis. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart.New York.
  • (PMID = 19688686.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


24. Viste A, Øvrebø K, Maartmann-Moe H, Waldum H: Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux. Gastric Cancer; 2004;7(1):31-5
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats.
  • The rats were then killed and the pH in the stomach and gastrin in blood were measured.
  • The stomach was examined macroscopically as well as histologically.
  • Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / physiopathology. Duodenogastric Reflux / complications. Duodenogastric Reflux / drug therapy. Enzyme Inhibitors / adverse effects. Omeprazole / adverse effects. Omeprazole / analogs & derivatives. Stomach Neoplasms / etiology. Stomach Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15052437.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Enzyme Inhibitors; 0 / Gastrins; 0K5C5T2QPG / Lansoprazole; KG60484QX9 / Omeprazole
  •  go-up   go-down


25. Tseng HH, Hsu PI, Chen HC, Lai KH, Lo GH, Lo CC, Chou NH, Mok KT, Chen IS, Chou NH, Yang HB, Liu L, Hsu PN: Compartment theory in Helicobacter pylori-associated gastric carcinogenesis. Anticancer Res; 2003 Jul-Aug;23(4):3223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was aimed at examining the compartment alterations through the Helicobacter pylori (H. pylori)-related chronic gastritis-intestinal metaplasia-carcinoma sequence, and investigating the long-term effect of bacterial eradication on the compartment changes.
  • PATIENTS AND METHODS: Gastric biopsy specimens were obtained from subjects with H. pylori-negative normal mucosa (N = 12), H. pylori-positive non-metaplastic gastritis (N = 42), H. pylori-positive intestinal metaplasia (N = 21) and intestinal-type adenocarcinoma (N = 20).
  • RESULTS: The mean PCNA labeling indices (L.I.) of non-metaplastic gastritis, intestinal metaplasia and adenocarcinoma were significantly higher than that of normal mucosa (31.1, 49.2 and 40.7 vs. 21.4; p < 0.01, 0.001 and 0.001, respectively).
  • In patients with intestinal metaplasia, there was a full expansion (phase 1 change) of proliferating zone to the middle compartment of gastric pits (ratio of L.I. between middle and lower compartment = 1.00).
  • The proliferating cells were evenly distributed in adenocarcinoma (complete loss of compartmentalization).
  • [MeSH-major] Adenocarcinoma / microbiology. Gastritis / microbiology. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Stomach Neoplasms / microbiology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Aged. Cell Cycle / physiology. Cell Division / physiology. Chronic Disease. Disease Progression. Drug Therapy, Combination. Female. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Humans. Lansoprazole. Male. Metaplasia / microbiology. Metaplasia / pathology. Metronidazole / therapeutic use. Middle Aged. Omeprazole / analogs & derivatives. Omeprazole / therapeutic use. Tetracycline / therapeutic use

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926056.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0K5C5T2QPG / Lansoprazole; 140QMO216E / Metronidazole; F8VB5M810T / Tetracycline; KG60484QX9 / Omeprazole
  •  go-up   go-down


26. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer; 2007 Apr 15;120(8):1803-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
  • The mammalian target of rapamycin (mTOR) has become an interesting target for cancer therapy through its influence on oncogenic signals, which involve phosphatidylinositol-3-kinase and hypoxia-inducible factor-1alpha (HIF-1alpha).
  • Since mTOR is an upstream regulator of HIF-1alpha, a key mediator of gastric cancer growth and angiogenesis, we investigated mTOR activation in human gastric adenocarcinoma specimens and determined whether rapamycin could inhibit gastric cancer growth in mice.
  • Expression of phospho-mTOR was assessed by immunohistochemical analyses of human tissues.
  • For in vitro studies, human gastric cancer cell lines were used to determine S6K1, 4E-BP-1 and HIF-1alpha activation and cancer cell motility upon rapamycin treatment.
  • Immunohistochemical analyses showed strong expression of phospho-mTOR in 60% of intestinal- and 64% of diffuse-type human gastric adenocarcinomas.
  • In vitro, rapamycin-treatment effectively blocked S6K1, 4E-BP-1 and HIF-1alpha activation, and significantly impaired tumor cell migration.
  • In vivo, rapamycin-treatment led to significant inhibition of subcutaneous tumor growth, decreased CD31-positive vessel area and reduced tumor cell proliferation.
  • In the dorsal-skin-fold chamber model, rapamycin-treatment significantly inhibited tumor vascularization in vivo.
  • In conclusion, mTOR is frequently activated in human gastric cancer and represents a promising new molecular target for therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Disease Models, Animal. Neovascularization, Pathologic / prevention & control. Protein Kinases / metabolism. Sirolimus / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Cell Hypoxia. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction. Survival Rate. TOR Serine-Threonine Kinases. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17230506.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


27. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep; 2005 Nov;14(5):1223-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
  • Fluoropyrimidines [5-Fluorouracil (5-FU) and its prodrugs] have been widely used in the treatment of solid cancers.
  • The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS).
  • In order to know the tumor types susceptible to respective fluoropyrimidines, we investigated the expression of DPD, OPRT, TP and TS in various types of cancer with the immunoperoxidase method.
  • These four enzymes existed in all of the cancer types studied, such as pulmonary, gastric, colorectal, hepatic, cholecystic, pancreatic, renal, urocystic, and mammary cancers.
  • Respective types of cancers presented characteristic immunohistochemical features as follows: pulmonary adenocarcinoma, DPD- and TP-high; pulmonary squamous cell carcinoma, TS- and TP-high; intestinal-type gastric adenocarcinoma, TP-high; diffuse-type gastric adenocarcinoma, DPD-low and TS-high; colorectal adenocarcinoma, DPD- and TP-low, hepatocellular carcinoma, DPD-high, and TS- and OPRT-low; cholecystic adenocarcinoma, DPD- and TS-high; renal cell carcinoma, DPD-low, and OPRT- and TP-high; urocystic transitional cell carcinoma, DPD-high and OPRT-low; and mammary ductal carcinoma, OPRT-low, and TS- and TP-high.
  • The enzyme expression pattern in cancer tissue was generally similar to that of their normal counterparts.
  • However, TP immunoreactivity in adenocarcinomas of the lung, stomach and gallbladder, and urothelial carcinoma of the urinary bladder was stronger, and DPD immunoreactivity in adenocarcinoma of the breast was weaker, when compared with normal epithelial cells.
  • Fluoropyrimidine treatment may be selected, based on the simultaneous immunohistochemical evaluation of the fluoropyrimidine metabolic enzymes.
  • [MeSH-major] Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / metabolism. Fluorouracil / pharmacology. Neoplasms / drug therapy. Neoplasms / enzymology
  • [MeSH-minor] Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Resistance. Humans. Immunohistochemistry. Orotate Phosphoribosyltransferase / metabolism. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211289.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimaki A: Cyclooxygenase-2 and gastric carcinogenesis. APMIS; 2003 Oct;111(10):915-25
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiological studies have shown that the use of nonsteroid anti-inflammatory drugs (NSAIDs) is associated with reduced risk of gastric cancer.
  • This suggests that Cox-2-derived prostanoids promote aggressive behavior of adenocarcinomas of the stomach.
  • Cox-2 expression is especially prominent in intestinal-type gastric carcinoma and it is already present in dysplastic precursor lesions of this disease, which suggests that Cox-2 contributes to gastric carcinogenesis already at the preinvasive stage.
  • Treatment of these mice with a Cox-2 selective inhibitor, celecoxib, reduced the size of the adenomas.
  • Taken together these data support efforts to initiate clinical studies to investigate the effect of Cox-2 inhibitors as chemotherapeutic agents and as adjuvant treatment modalities against gastric neoplasias.
  • [MeSH-major] Isoenzymes / metabolism. Prostaglandin-Endoperoxide Synthases / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / therapeutic use. Gene Expression. Humans. Membrane Proteins. Mice. Mice, Knockout. Models, Biological. Peptides / deficiency. Peptides / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616542.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Peptides; 0 / Tff1 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 76
  •  go-up   go-down


29. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, Sakata Y, Saito H, Miyata Y, Hyodo I, Ando M: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol; 2005 Dec;35(12):714-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall response rate and the median survival time were 55% (30/55) and 321 days, respectively.
  • Thirty patients with intestinal-type adenocarcinoma survived longer than 25 patients with diffuse-type (median survival time: 446, 259 days, P = 0.013).
  • The 39 patients having 2 or 3 favorable phenotypes (p53-negative, bcl-2-negative and VEGF-positive) survived longer than the remaining 16 patients (median survival time: 444, 259 days, P = 0.021).
  • In the Cox model, the number of the favorable phenotypes showed a tendency to correlate with survival after adjustment for potentially prognostic factors such as histological type or performance status (P = 0.070).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Glutathione S-Transferase pi / analysis. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303791.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A; 7673326042 / irinotecan; EC 2.5.1.18 / Glutathione S-Transferase pi; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Zivny J, Wang TC, Yantiss R, Kim KH, Houghton J: Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol; 2003 May-Jun;36(5 Suppl):S50-60; discussion S61-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of therapy or monitoring in preventing progression to gastric cancer.
  • It is generally accepted that intestinal-type gastric adenocarcinoma arises through a multistep process originating with chronic gastritis, progressing through stages of atrophy, intestinal metaplasia, and dysplasia and finally invasive carcinoma.
  • Intestinal metaplasia, however, does not appear to be as reversible.
  • Currently, in the United States, there is no widely accepted screening program for H. pylori infection in asymptomatic individuals, and consensus regarding surveillance for gastric intestinal metaplasia or dysplasia is lacking.
  • [MeSH-major] Adenocarcinoma / prevention & control. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Animals. Disease Progression. Gastritis, Atrophic / complications. Gastritis, Atrophic / pathology. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Metaplasia / pathology. Monitoring, Physiologic. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12702966.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


31. Rha SY, Jeung HC, Roh JK, Kim JJ, Noh SH, Min JS, Kim BS, Chung HC: Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Int J Mol Med; 2002 Sep;10(3):251-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.
  • To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9.
  • Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate.
  • Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues.
  • IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04).
  • In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups.
  • This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Matrix Metalloproteinase Inhibitors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Cell Differentiation. Female. Gabexate / pharmacology. Humans. Inhibitory Concentration 50. Male. Matrix Metalloproteinases / pharmacology. Middle Aged. Multivariate Analysis. Phenotype. Prognosis. Serine Proteinase Inhibitors / pharmacology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165796.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / Serine Proteinase Inhibitors; 4V7M9137X9 / Gabexate; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


32. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer.
  • Although HER-2 amplification occurs in more than 10% of gastric cancers, potential heterogeneity of HER-2 amplification and overexpression could represent a major drawback for anti-Her-2 therapy.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • Amplification was associated with intestinal tumor phenotype but unrelated to survival, grading, pT, pN, or pM.
  • The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down






Advertisement